Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms
Study Details
Study Description
Brief Summary
Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: PBOHB Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients |
Drug: Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound
To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Jaeger near uncorrected visual acuity improvement [1 hour]
Measure uncorrected near vision change after binocular instillation of PBOHB compound
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy
-
Presbyopic
-
40 - 60 years
Exclusion Criteria:
-
Diabetics
-
Previous eye surgery
-
Previous eye disease
-
0.50 myopia
-
1.5 hyperopia or astigmatism
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Optall Vision | Mexico City | Mexico | 01090 |
Sponsors and Collaborators
- Optall Vision
Investigators
- Principal Investigator: Cesar Alejandro S Galeana, MD, Optall Vision
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PBOPC02